Trials / Completed
CompletedNCT01069692
Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
A Double-blind, Randomized, Placebo-controlled Multi-center Trial to Compare the Phosphate Lowering Efficacy of Different Doses of SBR759 to Placebo
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare placebo to 4 different doses of SBR759 to assess the phosphate lowering efficacy in dialysis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SBR759A | SBR759A 6g daily |
| DRUG | SBR759A | Placebo Comparator 0g daily |
| DRUG | SBR759A | SBR759A 3g daily |
| DRUG | SBR759A | 9g daily |
| DRUG | SBR759A | 12g daily |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-10-01
- First posted
- 2010-02-17
- Last updated
- 2020-12-19
Locations
9 sites across 2 countries: Belgium, Italy
Source: ClinicalTrials.gov record NCT01069692. Inclusion in this directory is not an endorsement.